Some words come up over and over — in the exam room, on test results, in research news — without anyone stopping to explain them. They’re collected here.
What do Phase 1, 2 and 3 mean in clinical trials
The “Phase 1 / 2 / 3” labels you see on trial listings describe what that stage is trying to find out.
Early Phase 1
An exploratory step before a standard Phase 1, checking how a drug behaves in the body in a very small number of people over a short period. It has no treatment or diagnostic goal.
Phase 1
Focuses on safety. Usually run in a small number of participants, often healthy volunteers.
Phase 2
Gathers early evidence on whether the drug actually works, while safety continues to be monitored.
Phase 3
Gathers more evidence on safety and effectiveness across different groups and doses, with many more participants.
Phase 4
Happens after approval, to collect further information on safety, effectiveness and best use.
How likely is a drug to make it to the next stage
The published figures vary a lot between studies, so they’re listed by source rather than merged into one number.
- Phase 2 → Phase 3: 27–36% (Biostatistics, Wong 2019 / BIO·Biomedtracker, Thomas 2016)
- Phase 1 → final approval: 9.6–13.8% (Nature Biotechnology, Hay 2014 / Clinical Pharmacology & Therapeutics, DiMasi 2016)
- Phase 4 monitors an already-approved drug, so “success rate” doesn’t mean the same thing. We could not find reliable average figures for it, and would rather say so than guess.
Sources: FDA.gov, ClinicalTrials.gov glossary, Biostatistics (Wong 2019), Nature Biotechnology (Hay 2014), Clinical Pharmacology & Therapeutics (DiMasi 2016), BIO/Biomedtracker (Thomas 2016).
What are LRRK2, GBA and SNCA
The three genes that come up most often when Parkinson’s and inheritance are discussed. Genetics accounts for roughly 10–15% of cases.
LRRK2
The leucine-rich repeat kinase 2 gene. Variants here are associated with Parkinson’s that starts relatively later in life, and it is the most commonly implicated gene known so far. One variant, G2019S, is the most studied, and how often it appears varies enormously between populations — found in about 14% of Ashkenazi Jewish people with Parkinson’s and 30–40% of North African Berber people with Parkinson’s, but far rarer elsewhere. Inheriting it does not mean you will develop symptoms (see incomplete penetrance below): roughly 28% by age 59 and 74% by age 79. Drugs that inhibit LRRK2 activity are currently in clinical trials.
GBA
The gene for an enzyme called glucocerebrosidase, which breaks down lipids inside the cell’s lysosomes. Inheriting two altered copies causes a separate genetic condition, Gaucher disease; carrying just one copy does not cause Gaucher disease but does raise Parkinson’s risk. It is the most common Parkinson’s-related gene known — found in 5–20% of people with idiopathic Parkinson’s depending on ancestry, and in up to 9% of Ashkenazi Jewish people. GBA variants tend to come with faster cognitive decline and onset 3–11 years earlier on average.
SNCA
The gene for the alpha-synuclein protein. Variants are much rarer than in LRRK2 or GBA, but when present they show a clear autosomal dominant pattern and are associated with Parkinson’s starting at a relatively young age.
What is alpha-synuclein
A protein that is normally present in the brain. In Parkinson’s it clumps abnormally and builds up inside dopamine neurons; those clumps are called Lewy bodies. Finding them in the brain at autopsy is the classic pathological confirmation of Parkinson’s. Why the protein starts clumping, and why in some people and not others, is still not fully understood — it remains one of the most actively researched questions in the field.
What are the substantia nigra and basal ganglia
Substantia nigra
An area in the midbrain where the dopamine-producing nerve cells are concentrated. The name is Latin for “black substance”: as dopamine oxidizes naturally it produces a dark pigment called neuromelanin, which builds up in the cells here and makes the area visibly dark. In an autopsy of someone who had Parkinson’s, this area appears noticeably paler — the nerve cells are gone, and the pigment went with them.
Basal ganglia
The brain circuit that regulates movement. It draws on dopamine supplied by the substantia nigra to filter and fine-tune the movement commands coming down from the cerebral cortex. The pathway carrying dopamine from the substantia nigra to the striatum — part of the basal ganglia — is called the nigrostriatal pathway, and it is the first and most heavily affected part of the brain in Parkinson’s disease.
What are the DaTscan and Syn-One tests
DaTscan
A nuclear-medicine scan. A radioactive tracer (ioflupane I-123) is injected, and a special camera called a SPECT scanner images how much of it binds to the dopamine transporters (DAT) in the striatum. In a healthy brain the signal appears bright and symmetrical on both sides; where dopamine neurons have been lost, it appears weaker and lopsided. Importantly, this finding is not unique to Parkinson’s disease — other parkinsonian syndromes such as progressive supranuclear palsy can look abnormal in a similar way, so a DaTscan alone cannot confirm the diagnosis.
Syn-One test
A relatively recent test, in clinical use since 2019. Three tiny skin samples, about 3 mm across, are taken by biopsy — from the back of the neck, above the knee and above the ankle — and a special stain checks whether phosphorylated alpha-synuclein has built up in the small nerve fibers in the skin. It is used as supporting evidence, and also helps distinguish Parkinson’s from related conditions such as dementia with Lewy bodies.
What is a PET scan
Short for positron emission tomography. Where CT and MRI look at the shape of the brain, a PET scan looks at how the brain is actually working. It goes like this — a substance is built so that it sticks only to the thing being looked for (a particular protein or receptor), a very weak radioactive label is attached to it, and it is injected; the scanner then images which parts of the brain it collects in, and how much of it gathers there. That injected substance is called a tracer. Which tracer is used depends on what is being looked for: Parkinson’s research uses tracers that show dopamine nerve endings, tracers that show proteins tied to acetylcholine ([18F]VAT is one), and others besides.
One thing to be clear about, though: a research tracer is not a test you can ask for at an appointment. What gets used in a study and what is available as a clinical test are two separate things, and a tracer that looks useful in research still needs its own validation and approval before it reaches everyday care. The nuclear-medicine scan commonly used in diagnosing Parkinson’s is not PET but DaTscan, which uses SPECT (see the entry above).
What is acetylcholine
One of the neurotransmitters that carry signals in the brain and nerves. Parkinson’s is usually described as “a disease of too little dopamine”, but dopamine is not the whole of it. The nerve circuits that run on acetylcholine — the cholinergic system — weaken alongside the dopamine ones, and those circuits are the ones involved in memory, attention, visual processing, sleep and balance while walking.
That is why dopamine medication can ease tremor and stiffness while memory problems, visual hallucinations and frequent falls stay much the same — those symptoms are tied more closely to the acetylcholine side. A brain imaging study published in 2026 found that people whose acetylcholine activity was lower in the visual-processing areas of the brain had more severe visual hallucinations, and that among those with no hallucinations at the start, the ones with lower activity tended to develop them two to six years later.
It is also why acetylcholinesterase inhibitors (donepezil, rivastigmine and the like), the drugs used in dementia, are prescribed in Parkinson’s disease dementia as well — they slow the rate at which acetylcholine is broken down, so more of it stays available in the brain. Anticholinergic drugs work in the opposite direction, blocking the action of acetylcholine, and they are used cautiously in older people or where thinking has already declined, because they can worsen confusion and hallucinations.
What are paraquat and trichloroethylene
Paraquat
A herbicide. It is acutely and severely toxic if swallowed, and its use is restricted or banned in many countries. Separately from that acute danger, a number of studies have reported that long-term low-level exposure is associated with a higher risk of Parkinson’s disease, and Parkinson’s-related litigation against paraquat manufacturers is ongoing in the United States.
Trichloroethylene (TCE)
An industrial solvent used in dry cleaning and metal degreasing. It breaks down slowly and is a well-known groundwater contaminant. Studies of workers exposed to it over long periods have reported an association with Parkinson’s risk.
What are the Braak hypothesis and the vagus nerve
Braak hypothesis
Proposed by the German neuroanatomist Heiko Braak. It suggests that in some people alpha-synuclein begins clumping not in the brain but in the gut or the olfactory nerve, then travels up along the vagus nerve to the brain in a set sequence. If correct, it would help explain why non-motor symptoms such as constipation and loss of smell often appear years — sometimes more than a decade — before motor symptoms like tremor. Not everyone follows this sequence, so it remains a hypothesis.
Vagus nerve
A long nerve connecting the brain directly to organs in the neck, chest and abdomen. In the Braak hypothesis it is the route alpha-synuclein takes from the gut to the brain. Observational studies finding lower Parkinson’s rates in people who had previously had the vagus nerve cut (vagotomy) are cited as supporting evidence.
What are bradykinesia and rigidity
Bradykinesia
A general slowing of movement, and the hallmark motor symptom of Parkinson’s disease. It isn’t just about being slower: your stride may get shorter, and with a repeated movement — tapping your finger and thumb together, for instance — the size and speed of the motion tend to shrink as you keep going. Bradykinesia is a required criterion for a clinical diagnosis of Parkinson’s.
Rigidity
Stiffness in the limbs, another of the main motor symptoms. When a doctor slowly moves your arm or wrist, instead of gliding it may catch and release in a way that feels like a ratchet turning. That particular pattern is called cogwheel rigidity.
What are dyskinesia and motor fluctuations (on-off)
Dyskinesia
Involuntary writhing or swaying movements that develop after taking levodopa over a long period, as the brain becomes increasingly sensitive to dopamine. It isn’t caused by taking your medication wrongly — it reflects how the brain’s response to the drug changes as the disease progresses. It can look like tremor at a glance, but dyskinesia usually appears when the medication is working at its strongest (“on” time), and the shape of the movement is different. It is often managed by adjusting dose or timing.
Motor fluctuations and on-off
The alternation between “on” periods, when the medication is working, and “off” periods, when it wears away and symptoms return. Early on this tends to be fairly predictable — a “wearing-off” 30 minutes to an hour before the next dose — but as the disease progresses the switches can come suddenly and irregularly, with little relation to dose timing.
What is the UPDRS
The Unified Parkinson’s Disease Rating Scale. Where the Hoehn and Yahr scale sorts motor progression into a few broad stages, the UPDRS scores many separate items — non-motor areas such as cognition, behavior and mood, activities of daily living, individual motor signs, and treatment side effects — and adds them up. It has a lot of items and requires a neurologist to examine and score in person, so it is used more for tracking change over time in the clinic than for telling someone “what stage” they are.
What is aspiration pneumonia
Pneumonia caused when food or saliva goes into the airway instead of the esophagus (aspiration). As Parkinson’s progresses, the coordination of the swallowing muscles can weaken — dysphagia — which makes aspiration more likely. Thin liquids like water are often harder to swallow safely than thicker ones, so if you have symptoms, thickening food and drink or working with a speech-language pathologist on swallowing can help reduce the risk.
What are autosomal dominant and recessive inheritance
Autosomal dominant
An inheritance pattern where a variant from just one parent can be enough to cause the condition. LRRK2 and SNCA are inherited this way. Carrying the variant does not guarantee you will develop symptoms (see incomplete penetrance) — within the same family, one person may develop symptoms and another never will.
Autosomal recessive
An inheritance pattern requiring an altered copy from both parents. Each parent is a “carrier” with one copy and usually has no symptoms themselves. PRKN is associated with this pattern, and with early-onset Parkinson’s diagnosed at a relatively younger age.
What is PRKN
The gene for a protein called parkin, which is understood to tag damaged or misfolded proteins for disposal. PRKN is inherited in an autosomal recessive pattern and is one of the more common genetic causes of early-onset Parkinson’s (before 50, particularly in the 20s to 40s) — the younger someone is at diagnosis, the larger the role recessive genes like this one tend to play.
What are essential tremor and drug-induced parkinsonism
Essential tremor
The tremor condition most often confused with Parkinson’s. Parkinson’s tremor typically appears at rest and starts on one side of the body; essential tremor gets worse during movement — reaching for something, holding an object — and usually affects both sides. The head or voice may shake too. It is more common than Parkinson’s tremor, and the key difference is that it does not come with the other motor symptoms such as bradykinesia and rigidity.
Drug-induced parkinsonism
Some antipsychotics (such as haloperidol) and gut-motility drugs (such as metoclopramide) block dopamine receptors in the brain and can cause symptoms very similar to Parkinson’s — slowness, rigidity, difficulty walking. Unlike Parkinson’s it is usually symmetrical, and only about one in three people have tremor. Stopping the responsible drug often leads to gradual improvement over 4–18 months, though for some the symptoms persist (possibly because underlying Parkinson’s was already present and the drug brought it to the surface).
What are MSA, PSP and CBD
Conditions that look like Parkinson’s but progress differently and respond differently to treatment. They are grouped as atypical parkinsonism, or “Parkinson-plus syndromes.” They often respond less well to levodopa, and more than half of people with these conditions are initially diagnosed with Parkinson’s, with the correct diagnosis coming about three years later on average.
Multiple System Atrophy (MSA)
Marked by autonomic problems — severe dizziness on standing, large swings in blood pressure — and difficulty controlling urination.
Progressive Supranuclear Palsy (PSP)
Characterized by difficulty moving the eyes up and down. Balance problems and falls are severe from early on, changes in thinking and behavior start relatively early, and speech may become slurred.
Corticobasal Degeneration (CBD)
Characterized by stiffness with involuntary jerking on one side of the body, dystonia (limbs locking into abnormal postures), and poor limb coordination.
What are normal pressure hydrocephalus and vascular parkinsonism
Normal Pressure Hydrocephalus (NPH)
Caused by an excessive build-up of cerebrospinal fluid in the brain. The three classic symptoms are difficulty walking, cognitive slowing, and loss of bladder control. Unlike other parkinsonian conditions, symptoms can improve after a procedure to drain the fluid (such as a ventriculoperitoneal shunt), which makes distinguishing it particularly important.
Vascular parkinsonism
Parkinsonism caused by repeated damage to small blood vessels in the brain, including accumulated small strokes. It tends to affect the legs more than the arms (“lower-body parkinsonism”), rest tremor is rare, and the response to levodopa is markedly weaker than in Parkinson’s — studies report only partial response in roughly 20–40%.
What is dementia with Lewy bodies (DLB)
A dementia caused by Lewy bodies (clumped alpha-synuclein) accumulating widely across the brain. It is characterized by memory problems and confusion, difficulty sustaining attention, visual hallucinations, and motor symptoms similar to Parkinson’s. People with Parkinson’s can also develop dementia after many years (Parkinson’s disease dementia); the two are distinguished by which came first, and how early — if motor symptoms came first and dementia followed more than a year later, it is usually called Parkinson’s disease dementia; if cognitive symptoms arrived at about the same time as, or before, the motor symptoms, it is usually called DLB.
What is LSVT LOUD
The most widely used specialist voice therapy program for the speech and voice problems of Parkinson’s. It runs for four weeks, four sessions a week, 16 sessions in total, and concentrates on a single deceptively simple thing: speaking loudly. Despite that simplicity, it has been reported to improve intonation and articulation accuracy as well, with benefits lasting up to two years. It is now also available remotely.
What is a protein redistribution diet
When levodopa is absorbed from the gut into the brain, it competes for the same transport route as amino acids from digested protein. A protein redistribution diet shifts most of the day’s protein to the evening meal, keeping daytime protein low so the medication works as well as possible during active hours. Some studies report it reduces motor fluctuations for certain people, but responses vary and over-restricting can lead to weight loss and poor nutrition — so it should be adjusted together with a dietitian and your care team.
What is REM sleep behavior disorder (RBD)
During sleep the muscles normally relax; in RBD that control fails and the person physically acts out their dreams — shouting, moving their arms and legs. Up to half of people with Parkinson’s are reported to experience it, and it often appears 5–10 years before motor symptoms, which makes it a relatively early signal. Medications such as clonazepam are reported to improve it in about 80–90% of cases.
What is restless legs syndrome (RLS)
An uncomfortable sensation in the legs with a strong urge to move them. It gets worse when lying down or sitting still and eases temporarily with movement. It is sometimes linked to low iron, so if you suspect it, it’s worth having iron levels checked with a blood test.
What are dystonic pain and central pain
Dystonic pain
Pain from muscles twisting or cramping involuntarily and continuously. It commonly shows up as toes curling under or the ankle twisting inward, and often worsens when medication is wearing off. Muscle relaxants, botulinum toxin (Botox) injections and deep brain stimulation (DBS) can help.
Central pain
Pain caused by the sensory and pain-regulating pathways in the brain and spinal cord not working properly. It is often felt as burning or tingling, without any injury or pressure at the site. Anticonvulsant and antidepressant medications are known to help.
What is mild cognitive impairment (MCI)
Thinking that has slowed somewhat compared with others of the same age, but not enough to interfere with managing daily life independently. In Parkinson’s it tends to affect attention and executive function (handling several things in sequence) more than pure memory. Not all MCI progresses to dementia, and managing it early can slow the decline — in some cases partly reverse it.
What is apathy
A loss of motivation and interest in starting things, without feeling sad or depressed. What distinguishes it from depression is that the person is often not particularly troubled by the state itself. It is easily mistaken for laziness or indifference, but it is a neurological symptom arising from reduced dopamine and other brain chemicals.
What is Parkinson’s disease psychosis
The umbrella term for hallucinations (seeing or hearing things that aren’t there) and delusions (firmly believing things that aren’t true) in Parkinson’s. Parkinson’s medications themselves — levodopa and dopamine agonists — are frequently the cause, and dementia or a sudden change in awareness (delirium) can also be responsible. Visual hallucinations are reported in 20–30% of people with Parkinson’s.
What is a dopamine agonist
A medication that acts in place of dopamine in the brain. It is prescribed alongside levodopa or on its own, and helps control motor symptoms. It carries a markedly higher risk of impulse control disorder than levodopa, so if you are taking one it is worth watching carefully for changes in behavior.
What is an impulse control disorder (ICD)
Being unable to stop a behavior that is harmful, or could become harmful. A characteristic feature is a feeling of relief from anxiety or tension when the behavior is carried out. In Parkinson’s it is linked to dopamine agonists, and the most commonly reported forms are compulsive gambling, excessive shopping, binge eating and hypersexuality.
What is dopamine dysregulation syndrome
Taking more medication, more often, than prescribed. It can show up as anxiety when trying to cut back, or quietly taking extra doses. It shares a cause with impulse control disorder — the effect of dopamine medication on the brain’s reward circuitry — and the two often occur together, but ICD fixates on a behavior such as gambling or shopping, while dopamine dysregulation syndrome fixates on the medication itself. It is not a matter of weak willpower, so rather than hiding medication or arguing about it, it is safer to work out a dosing arrangement with the care team.
Source: Parkinson’s Foundation, “Impulse Control Disorders”.
What is punding
Repeating the same purposeless activity over and over — collecting things, taking objects apart and reassembling them, tidying a drawer and then emptying it again. It is more common at higher doses of dopamine medication, and particularly when dopamine dysregulation syndrome is also present.
Source: Parkinson’s Foundation, “Impulse Control Disorders”.
What is nocturnal akinesia
Difficulty turning over or changing position during sleep. Like daytime motor symptoms it develops as Parkinson’s progresses, and up to 70% of people in the mid-stages and beyond are reported to experience it. Staying pressed in one position for long periods carries a risk of complications such as pressure sores and aspiration pneumonia, so it is more than a matter of discomfort. Some studies report improvement from taking a slow-release (extended-release) levodopa formulation at bedtime.
Sources: Parkinson’s Foundation, Michael J. Fox Foundation, NEJM (Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson’s Disease).
What is a dopamine blocker
A medication that works in exactly the opposite way to a dopamine agonist: instead of standing in for missing dopamine, it blocks the dopamine receptors themselves. These are common medications for people without Parkinson’s, but giving them to someone with Parkinson’s can worsen symptoms sharply, so they are classed as drugs to avoid. The ones to know include antipsychotics such as haloperidol, chlorpromazine, risperidone, olanzapine, aripiprazole and amisulpride, and gut-motility and anti-nausea drugs such as metoclopramide and prochlorperazine. Because they are prescribed by many specialties — not just neurology — it is important to mention your Parkinson’s whenever you see a new doctor, not only in hospital or the emergency department. Ondansetron (anti-nausea) and quetiapine, clozapine and pimavanserin (antipsychotics) are generally considered safer alternatives.
Source: American Parkinson Disease Association, “Medications to Avoid with Parkinson’s Disease”.
What are phenothiazines
A class of medication long used in psychiatry as antipsychotics and anti-nausea drugs (chlorpromazine among them). They block dopamine receptors, which makes them dopamine blockers, and they can sharply worsen symptoms in people with Parkinson’s. They are also occasionally used as an anesthetic adjunct during surgery, so if you are having an operation, make sure the anesthesiology team knows you have Parkinson’s.
Source: American Parkinson Disease Association, “Medications to Avoid with Parkinson’s Disease”.
What is a MAO-B inhibitor
A medication that inhibits an enzyme called monoamine oxidase B, slowing the rate at which dopamine is broken down in the brain. It works differently from levodopa, which supplies new dopamine, but the result is similar — dopamine stays available longer, easing symptoms. Selegiline and rasagiline are the main examples. Interactions with local anesthetics containing epinephrine, at the dentist for instance, were once a significant concern; more recent work suggests serious problems are unlikely at standard doses. Still, always mention that you take one before any procedure, so the dose can be adjusted carefully if needed.
Sources: Parkinson’s Foundation, “Dental Health in PD”; Specialist Pharmacy Service (NHS), “Managing interactions with local anaesthetics in dentistry”.
What is a COMT inhibitor
A medication that blocks catechol-O-methyltransferase, the enzyme that breaks levodopa down in the body before it reaches the brain. It does nothing on its own, so it is never taken alone — it is always given alongside levodopa, and is often dispensed as a single combined tablet with it. Entacapone and opicapone are the common ones. It is usually added when the benefit from each levodopa dose starts wearing off sooner than it used to, to stretch that window back out. Urine can turn a dark orange-ish colour from the drug itself, which is harmless.
What is an extended-release formulation
A tablet or capsule built so the medication is let out slowly, a little at a time, instead of all at once. The opposite is an immediate-release formulation.
The distinction matters most with levodopa. Immediate-release starts working quickly but does not last; extended-release lasts longer but takes longer to start. Some people are prescribed immediate-release during the day and an extended-release form at bedtime, when stiffness overnight is the problem. Newer products put immediate-release granules and extended-release beads in the same capsule to get both properties at once.
Do not split or chew an extended-release tablet. Breaking it destroys the structure that releases the drug slowly, so the whole dose is let out at once. If a tablet is hard to swallow, do not cut it on your own — say so to your neurologist or pharmacist.
One more thing: extended-release forms are absorbed less predictably than immediate-release ones, so the same number of milligrams does not translate one-to-one. That is why the dose is always adjusted by prescription when the formulation changes, rather than carried straight across.
Source: Parkinson’s Foundation, “Medications for Motor Symptoms”; Michael J. Fox Foundation.
What is a PDE5 inhibitor
A class of oral medication used for erectile dysfunction (sildenafil is the best-known). It works by widening blood vessels to increase blood flow. It is not thought to interact strongly with Parkinson’s medications, but if you also take blood-pressure medication your blood pressure could drop too far — so tell your care team everything you are taking before it is prescribed.
Source: Parkinson’s Foundation, “Sexual Health”.
What is deep brain stimulation (DBS)
Surgery that places thin electrodes deep in the brain (most often the subthalamic nucleus) to deliver continuous fine electrical stimulation. It is considered for people whose symptoms are no longer well controlled by medication alone, or whose dyskinesia has become severe, and studies show greater improvement in motor function when it is combined with medication than with medication alone. If you have a device, you need to tell clinical staff in advance before procedures — especially MRI scans and surgery — and airport security staff before going through screening.
What is transcranial direct current stimulation (tDCS)
A non-surgical stimulation method that passes a weak direct current into areas near the surface of the brain through electrodes placed on the scalp. Unlike DBS, it needs no surgery to implant electrodes and no anesthesia, so the burden is far lower. A session usually runs 20–30 minutes and it is studied as a repeated course rather than a one-off. It is still at the research stage, as an add-on for non-motor symptoms such as low mood and apathy, and is not an established standard treatment the way DBS is.
What is incomplete penetrance
The fact that inheriting a particular gene variant does not necessarily mean you will develop the condition. Within the same family, carrying the same variant, one person may develop symptoms and another never will. For LRRK2, for example, the reported chance of actually developing Parkinson’s rises with age — about 28% by 59, 51% by 69 and 74% by 79. The risk climbs with age, but a substantial number of people live their whole lives without symptoms.
Source: Parkinson’s Foundation, “Is Parkinson’s Genetic?”.
What is young-onset Parkinson’s (YOPD)
Parkinson’s diagnosed before age 50, also called early-onset Parkinson’s (EOPD). About 4% of people with Parkinson’s in the United States fall into this group. The core symptoms are the same as in the more common later-onset form, but there are some differences. Genetics plays a much larger role the younger the onset: a specific gene variant is found in 65% of those who develop it before 20, and 32% of those who develop it between 20 and 30. Progression tends to be slower overall and cognitive problems leading to dementia are less common, but dystonia — muscles in the foot twisting inward — often appears early, and because treatment runs for many more years, medication side effects such as dyskinesia tend to arrive sooner too. People are often diagnosed while building a career or raising children, so the psychological weight around work and family planning is particularly heavy.
Source: Parkinson’s Foundation, “Young-Onset Parkinson’s”.
What is care partner burnout
A term the Parkinson’s Foundation uses to describe how the weight of caregiving builds up, in three stages. It starts as manageable care partner stress. Over time that stress accumulates into care partner strain, which begins to affect the ability to provide care at all. Left unaddressed, physical, emotional and mental exhaustion pile up until the care partner starts withdrawing from the role while neglecting their own health — care partner burnout. What marks it out is not simply “finding it hard,” but a change in attitude toward caregiving itself: things that were once routine suddenly feel unbearable, resentment toward the person you care for builds, or the thought “I want to stop” keeps returning. Surveys have found that around half of care partners under severe stress meet the clinical criteria for depression — so if the warning signs have been there for weeks, that is the point to get professional help rather than push through.
Sources: Parkinson’s Foundation, “How to Address and Prevent Care Partner Burnout” · “Caring for the Care Partner”.
What is the difference between assisted living and a nursing home
The names get used loosely, but they describe different levels of care. Assisted living is primarily residential: help with everyday activities such as bathing, dressing, medication reminders and meals, for people who don’t need continuous medical supervision. A nursing home (skilled nursing facility) provides ongoing nursing and medical care, with licensed clinical staff on site. The practical question is whether what’s needed right now is help with daily living or ongoing medical care.
Which services exist, what they’re called and how they’re paid for vary considerably by country and — in the United States — by state and by insurance or Medicaid status. A social worker at your clinic or hospital is usually the fastest way to find out what applies to your situation.
What is a durable power of attorney
A legal document you complete while you still have decision-making capacity, naming someone you choose to make decisions on your behalf if you later cannot. It is usually distinguished from arrangements made after capacity is lost, where a court appoints a guardian or conservator — with a power of attorney, you choose the person yourself, in advance.
There is usually a separate document for healthcare decisions and for financial ones, and the exact names, forms and witnessing or notarization rules differ by jurisdiction. If symptoms affecting judgment have not appeared yet, or are still mild, preparing early is the surest way to have your own wishes recorded about who will act for you.
What is an advance directive
A document recording, in advance, what medical treatment you would or would not want at the end of life — particularly treatments that would prolong life without a realistic prospect of recovery. It is completed by you, while you are able to make the decision, and can be changed or withdrawn at any time.
This is distinct from orders written by a physician for someone already in the final stage of an illness (such as a POLST or DNR order), which differ in who writes them and when. The specific forms, and how they must be witnessed and registered to be legally effective, vary by jurisdiction — your care team or a hospital social worker can point you to the right one.
What is a driver medical review
A process, separate from routine license renewal, for assessing whether a medical condition affects someone’s fitness to drive. It can be triggered by self-reporting, by a clinician’s report, or by the licensing authority. It typically involves submitting medical documentation, and sometimes an in-person driving assessment. The outcome may be continuing to drive with conditions attached, or losing the license.
A Parkinson’s diagnosis on its own does not automatically mean losing your license — fitness to drive is assessed individually. Who must report what, and when, differs by country and by US state, so check the rules for where you live rather than assuming.
Words that come up in benefit paperwork
Benefit systems differ by country, but a handful of words decide whether an application succeeds. These are the ones people most often misread.
Substantial gainful activity (United States)
The monthly earnings level above which the Social Security Administration generally will not treat you as having a qualifying disability — no matter what your medical records show. It is an earnings test, applied before anyone looks at how you are actually doing.
This catches people out because it works in the opposite direction from what feels fair: someone who keeps working part-time to stay afloat can be ruled out on earnings alone. The dollar figure is set each year, so check the current one rather than a number you read somewhere.
Functional capacity (Australia and elsewhere)
Your practical ability to do daily activities — communicating, socialising, learning, moving around, looking after yourself, managing your life.
Note what this is not: it is not your diagnosis, and it is not a list of your symptoms. An assessor is asking what you can and cannot do on an ordinary day. For Parkinson’s this is where fluctuation matters most — if you describe only your best hour, that is the capacity that gets recorded.
Non-refundable (Canada and elsewhere)
A tax credit that can reduce the income tax you owe down to zero, but cannot turn into a refund on its own if you owe nothing.
This is why people with little or no taxable income sometimes conclude a credit is worthless to them and never apply. That can be a mistake — in some systems the credit can be transferred to a supporting family member, and in others being approved for the credit is the gateway to other programs. Apply first, then work out who claims it.
Creditable drug coverage (United States)
Prescription drug coverage that is expected to pay, on average, at least as much as Medicare drug coverage — for example from a current or former employer, TRICARE, the VA, or the Indian Health Service.
Why it matters: if you go without creditable coverage and enrol in Medicare drug coverage later, a late enrolment penalty can be added to your premium and stay there. Keep the letter that tells you whether your coverage is creditable.
Rest home care and hospital-level care (New Zealand)
Rest home care is help with daily living in a residential setting. Hospital-level care is continuous nursing care.
The point people miss: the level you are assessed as needing determines the type of facility, not your preference. The needs assessment comes first, and the funding follows the assessed level.
